CAS 1379573-88-2

4-[[3-[4-(4-Carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-nitrophenyl]methyl]piperazine-1-carboximidamide

CAS : 1379573-88-2

4-[[3-[4-(4-Carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-nitrophenyl]methyl]piperazine-1-carboximidamide (PPCI) is a potent and selective inhibitor of the NMDAR. PPCI also inhibits the activity of voltage gated potassium channels, alpha7 nicotinic acetylcholine receptors and 5HT3 serotonin receptors. It has been reported to be a promising candidate for the treatment of Alzheimer's disease and other neurological disorders that are characterized by excitotoxicity. PPCI is an important research tool for studies on receptor interactions, ion channels, cell biology, pharmacology, and neuroscience.
PPCI was first synthesized in 2006 by scientists from Merck Research Laboratories.br>br>

Formule : C₂₅H₃₁N₉O₄

Degré de pureté : Min. 95%

Masse moléculaire : 521.6 g/mol

Ref: 3D-EFC57388

CBB1003

CAS : 1379573-88-2

CBB1003 is a new inhibitor of histone demethylase LSD1 (IC50: 10.54 μM).

Formule : C₂₅H₃₁N₉O₄

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 521.57

Ref: TM-T10698